Ritonavir-Saquinavir Dual Protease Inhibitor Compared to Ritonavir Alone in Human Immunodeficiency Virus-Infected Patients

The objective of this study was to evaluate the antiretroviral efficacy and safety of ritonavir (600 mg twice a day [b.i.d.])-saquinavir (400 mg b.i.d.) compared to ritonavir (600 mg b.i.d.) in patients pretreated and receiving continued treatment with two nucleoside analogs. The study was placebo c...

Celý popis

Podrobná bibliografie

Vydáno v:	Antimicrob Agents Chemother
Hlavní autoři:	Michelet, Christian, Ruffault, Annick, Sébille, Véronique, Arvieux, Cedric, Jaccard, Philippe, Raffi, François, Bazin, Claude, Chapplain, Jean-Marc, Chauvin, Jean-Pierre, Dohin, Elisabeth, Cartier, François, Bellissant, Eric
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	American Society for Microbiology (ASM) 2001
Témata:	Antiviral Agents
On-line přístup:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC90843/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11709314/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.45.12.3393-3402.2001
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!